Sodium valproate tablets

This product is an anti-epileptic drug. Its mechanism of action has not been fully elucidated. Experiments show that this product can increase the synthesis of GABA and reduce the degradation of GABA, thereby increasing the concentration of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), reducing the excitability of neurons and inhibiting seizures. In electrophysiological experiments, it was found that this product can produce an inhibitory effect on Na channels similar to phenytoin. It is harmful to the liver.

The main ingredient of this product is sodium valproate, and its chemical name is: 2-sodium valproate

This product is a white sugar-coated tablet, which appears white or off-white after removing the sugar coating.

It is mainly used for the treatment of simple or complex absence seizures, myoclonic seizures, and grand mal seizures as a single drug or in combination. It sometimes also has a certain effect on complex partial seizures.

Common dosage for adults: 15 mg/kg per day or 600~1200 mg per day divided into 2~3 times. Start with 5~10 mg/kg, increase gradually after one week until the attack can be controlled. When the daily dosage exceeds 250 mg, it should be taken in divided doses to reduce gastrointestinal irritation. The maximum daily dosage is no more than 30 mg/kg per day, or 1.8~2.4 g per day. Common dosage for children: The same as that for adults, 20~30 mg/kg per day, divided into 2~3 times or 15 mg/kg per day, increase by 5~10 mg/kg every other week as needed, until effective or intolerable.

1 Common adverse reactions include diarrhea, indigestion, nausea, vomiting, gastrointestinal spasm, and changes in menstrual cycle. 2 Less common are transient hair loss, constipation, drowsiness, dizziness, fatigue, headache, ataxia, mild tremor, abnormal excitement, restlessness and irritability. 3 Long-term use may occasionally cause pancreatitis and acute liver necrosis. 4 It may cause thrombocytopenia, purpura, bleeding and prolonged bleeding time, and blood tests should be conducted regularly. 5 It may damage liver function, causing elevated serum alkaline phosphatase and aminotransferase. Liver function tests should be conducted after 2 months of use. 6 Occasionally allergic reactions occur. 7 Occasionally there may be hearing loss and reversible hearing damage.

Patients with a personal or family history of drug-induced jaundice, liver disease or obvious liver damage are contraindicated. Patients with blood disease, liver disease history, renal damage, or organic encephalopathy should use with caution.

Precautions for children: This product can accumulate in developing bones, so be careful. Precautions for pregnancy and lactation: This drug can pass through the placenta, and there are reports of teratogenicity in animal experiments. Pregnant women should weigh the pros and cons and use it with caution. This product can also be secreted into breast milk, with a concentration of 1-10% of the maternal blood drug. It should be used with caution. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

(1) Drinking alcohol can increase the sedative effect. (2) When general anesthetics or central nervous system depressants are used in combination with valproic acid, the clinical effect of the former may be more obvious. (3) When used in combination with anticoagulants such as warfarin or heparin, as well as thrombolytics, the risk of bleeding increases. (4) When used in combination with aspirin or dipyridamole, the bleeding time may be prolonged due to reduced platelet aggregation. (5) When used in combination with phenobarbital, the metabolism of the latter slows down and the blood drug concentration increases, thereby increasing the sedative effect and causing drowsiness. (6) When used in combination with primidone, it may also cause an increase in blood drug concentration and lead to poisoning. If necessary, the dosage of primidone should be reduced.

Sealed, stored in a dry place

0.1g

30 months.

Hunan Xiangzhong Pharmaceutical Co., Ltd.

• Founded in:

  1998-03-05

• Address:

  No. 18, Daxing South Road, Baoqing Industrial Concentration Zone, Shaoyang City, Hunan Province

• Tax NO.:

  91430500185569358T

• Registered Funds:

  69 million yuan

• Website:

  Log in to view

• Email:

  Log in to view